{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-female-genital/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"17acaa38-dc82-5062-9b9e-b70e43844f09","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field dfc4c475-5ddb-41d5-b92c-3b1e086491b8 --><h2>Changes</h2><!-- end field dfc4c475-5ddb-41d5-b92c-3b1e086491b8 -->","summary":null,"htmlStringContent":"<!-- begin item 65182bb3-14ef-48ac-81ca-1c0e15d18228 --><!-- begin field ab97b771-5868-47a4-9120-acb53dc713a5 --><p><strong>May 2017 </strong>— minor update. The prescribing information section has been simplified. Minor typographical errors have been corrected.</p><p><strong>December 2016 </strong>— minor update. The adverse effects and interactions for fluconazole have been updated in line with the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015a</a>].</p><p><strong>November 2016</strong> — reviewed. A literature search was conducted in October 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. No major changes to recommendations have been made, but the topic has been restructured.</p><!-- end field ab97b771-5868-47a4-9120-acb53dc713a5 --><!-- end item 65182bb3-14ef-48ac-81ca-1c0e15d18228 -->","topic":{"id":"99e20f18-68df-560d-b5d3-b6ec31ccad61","topicId":"1a8f74c5-56a3-4356-a328-97bd2f790f35","topicName":"Candida - female genital","slug":"candida-female-genital","lastRevised":"Last revised in May 2017","chapters":[{"id":"de1ba63a-d3be-5e38-9afa-2decfb6a4104","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"70e5dc95-dca6-5aed-ba02-7677e5595791","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7785eebb-7adf-5829-8438-054465d94780","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"17acaa38-dc82-5062-9b9e-b70e43844f09","slug":"changes","fullItemName":"Changes"},{"id":"3fde567e-3066-57d8-be3e-016c389f8b94","slug":"update","fullItemName":"Update"}]},{"id":"7bdd785b-dd70-5bde-a56b-ece7a71c1890","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2aea51d9-2817-5901-8b3f-003e41a1f1b9","slug":"goals","fullItemName":"Goals"},{"id":"16c71775-c8a9-58f1-b6e8-00d83ea3e32a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"584f77ef-93e6-5c84-93b4-8331fed80193","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ffb6e4fa-b86a-5191-9bbb-c113c86952b6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cc13b04c-c8b4-5403-a61e-10f784bc17de","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ba1a16f-d8bd-55bc-8208-17beaddd9264","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"d90c278f-fcf0-5c7c-aeab-b0decc2194dd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5d851a40-f1f9-50de-b7de-3e374a862b45","slug":"definition","fullItemName":"Definition"},{"id":"51060b0d-4f1d-5133-9645-6efc6b9ca9d8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c7dd35c5-dc87-55a0-b15e-5fd3c5f79ede","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bcbc381a-db1c-5df4-a8fa-cb1ce02a4ab3","slug":"complications","fullItemName":"Complications"},{"id":"2ec519a6-61da-53cb-b5c6-e53420e1f175","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1296609f-72a1-5634-918b-eb0f9bf2b217","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"197fc582-d823-5341-813b-4d48a895ac84","slug":"assessment","fullItemName":"Assessment"},{"id":"7fa609e6-64b1-5e1e-a2fe-9d8aaae57662","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b7ed2787-e953-5da0-ba29-6ad5d5aa7138","fullItemName":"Management","slug":"management","subChapters":[{"id":"0d8e43cc-e312-572a-97eb-50ab1223bf29","slug":"uncomplicated-infection","fullItemName":"Scenario: Uncomplicated infection"},{"id":"20ef6f32-4f35-577b-af2b-0479dafd7a6f","slug":"severe-infection","fullItemName":"Scenario: Severe infection"},{"id":"19018671-1df6-546c-a24e-c0277342e2e1","slug":"recurrent-infection","fullItemName":"Scenario: Recurrent infection"},{"id":"0f525c4d-623c-5b02-9045-c7f9c57692e4","slug":"diabetes-or-immunocompromised","fullItemName":"Scenario: Diabetes or immunocompromised"},{"id":"d143d272-2856-5fad-95fe-708b221847f0","slug":"during-pregnancy","fullItemName":"Scenario: During pregnancy"}]},{"id":"fa8e2e27-5ea4-5088-86f8-65ffd101ec26","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a11071ae-b868-56f6-a390-4809b91594ea","slug":"choice-of-antifungals","fullItemName":"Choice of antifungals"},{"id":"169ff7be-fabd-556e-bdf3-92c30e390f3d","slug":"intravaginal-antifungals","fullItemName":"Intravaginal antifungals"},{"id":"cca352b0-a363-5b43-97d2-9df0dbf242b6","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"754e0483-3f11-5510-9b98-7f8c44679e56","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"2ae3a41b-64fa-5372-baba-bb8c04e033d8","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"dd75ee8e-5efd-51c0-bcc2-3af7ee1253e7","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"74d9d85c-590f-5e29-a202-78d94a6f747f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d7a69713-bc5d-57da-9132-ff07c7fef62c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a8d93477-c70c-5177-92d7-e96545a6b2f7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4841d69e-1e2b-5aec-9c3b-1ea8cd8bbf08","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b3113b9f-1b0e-5987-99b4-e616eb6d128a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e41c5da-d9a8-5c0d-bb7f-f68cda4acb05","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6eb1b4a4-5ae4-5a59-8ca6-6434652b9454","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7785eebb-7adf-5829-8438-054465d94780","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"1d3e33b1-a91e-55dd-887e-4a4fafe155b7","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 4ea35e05-ba37-48e9-9f6c-50cf0a01026f --><h3>Previous changes</h3><!-- end field 4ea35e05-ba37-48e9-9f6c-50cf0a01026f -->","summary":null,"htmlStringContent":"<!-- begin item 4527eadc-bbb4-4a53-8a98-96544481a07d --><!-- begin field 37569ff5-4400-438e-82ec-78149700ae0d --><p><strong>December 2013 </strong>— minor update. Text updated to reflect that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has suspended the marketing authorization for oral ketoconazole. It should no longer be prescribed for the treatment of fungal infections.</p><p><strong>August 2013 </strong>— minor update to the text to reflect recent guidance from the EMA regarding the use of oral ketoconazole.</p><p><strong>August 2012 </strong>— reviewed. A literature search was conducted in July 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. Changes to clinical recommendations have been made, including syndromic management of uncomplicated vulvovaginitis and management of non-albicans <em>Candida</em> infection. Changes to drug regimens for the treatment of <em>Candida</em> infection, including those for induction and maintenance, have been made.</p><p><strong>September 2011 </strong>— minor update. The Cochrane systematic review <em>Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection </em>is cited regarding the treatment of immunocompromised women, and in the section on recurrent infection. Issued in September 2011.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>May 2010 </strong>— minor update. The manufacturer of econazole 1% cream (Pevaryl<sup>®</sup>) states that it is not recommended for use during pregnancy. The prescription has been removed. Issued in May 2010.</p><p><strong>March 2010 </strong>— minor update. Results of the updated Cochrane systematic review on oral compared with intra-vaginal imidazole and triazole antifungal treatment of uncomplicated vulvovaginal candidiasis have been updated. Issued in March 2010.</p><p><strong>May 2009 </strong>— minor update. Econacort-1<sup>®</sup>pessaries have been discontinued, so the prescription has been removed. Other intravaginal econazole preparations remain available. Issued in June 2009.</p><p><strong>February 2009 </strong>— minor update. Nystatin intravaginal cream (Nystan<sup>®</sup>) has been discontinued. The prescription has been removed, and the relevant text has been updated. Issued in March 2009.</p><p><strong>January 2009 </strong>— minor update. Gyno-Daktarin<sup>®</sup>pessaries have been discontinued. The prescription has been removed, and the relevant text has been updated. Issued in February 2009.</p><p><strong>June to September 2007 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>April 2008 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) guidance regarding oral ketoconazole has been added.</p><p><strong>February 2008 </strong>— minor update. Late comments from the British Association for Sexual Health and HIV (BASHH) have been included. Gyno-pevaryl 1 combination pack has been discontinued. The prescription has been removed, and the relevant text has been updated. Issued in March 2008.</p><p><strong>March 2004 </strong>— reviewed. Validated in May 2004 and issued in July 2004.</p><p><strong>January 2001 </strong>— reviewed. Validated in March 2001 and issued in June 2001.</p><!-- end field 37569ff5-4400-438e-82ec-78149700ae0d --><!-- end item 4527eadc-bbb4-4a53-8a98-96544481a07d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}